William Blair initiated coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS) in a research report sent to investors on Wednesday. The firm issued an outperform rating on the biotechnology company’s stock. William Blair also issued estimates for Pieris Pharmaceuticals’ Q4 2017 earnings at $0.14 EPS, FY2017 earnings at ($0.44) EPS, FY2018 earnings at ($0.70) EPS, FY2019 earnings at ($0.86) EPS, FY2020 earnings at ($1.01) EPS, FY2021 earnings at ($1.77) EPS and FY2022 earnings at ($1.84) EPS.

Other research analysts also recently issued research reports about the stock. HC Wainwright set a $9.00 price objective on shares of Pieris Pharmaceuticals and gave the stock a buy rating in a report on Monday, October 2nd. BidaskClub upgraded shares of Pieris Pharmaceuticals from a hold rating to a buy rating in a report on Wednesday, December 27th. Finally, ValuEngine downgraded shares of Pieris Pharmaceuticals from a hold rating to a sell rating in a report on Friday, December 1st. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $10.00.

Pieris Pharmaceuticals (NASDAQ PIRS) traded up $0.05 during trading on Wednesday, hitting $7.42. 551,922 shares of the company were exchanged, compared to its average volume of 479,391. Pieris Pharmaceuticals has a 52 week low of $1.66 and a 52 week high of $7.90. The firm has a market cap of $332.37, a P/E ratio of -10.03 and a beta of 1.79.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.05. Pieris Pharmaceuticals had a negative net margin of 321.83% and a negative return on equity of 221.93%. The company had revenue of $3.93 million for the quarter, compared to the consensus estimate of $1.52 million. The company’s revenue was up 400.3% compared to the same quarter last year. analysts predict that Pieris Pharmaceuticals will post -0.62 EPS for the current year.

In other Pieris Pharmaceuticals news, major shareholder Orbimed Advisors Llc sold 1,709,620 shares of the company’s stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $7.35, for a total transaction of $12,565,707.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.05% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PIRS. Voya Investment Management LLC bought a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter worth $100,000. Wells Fargo & Company MN bought a new stake in shares of Pieris Pharmaceuticals in the 3rd quarter worth $105,000. Bank of Montreal Can bought a new stake in shares of Pieris Pharmaceuticals in the 4th quarter worth $144,000. The Manufacturers Life Insurance Company grew its stake in shares of Pieris Pharmaceuticals by 1,106.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,785 shares of the biotechnology company’s stock worth $161,000 after acquiring an additional 29,150 shares in the last quarter. Finally, Rhumbline Advisers bought a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter worth $184,000. Hedge funds and other institutional investors own 50.45% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Pieris Pharmaceuticals (PIRS) Now Covered by Analysts at William Blair” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.watchlistnews.com/pieris-pharmaceuticals-pirs-now-covered-by-analysts-at-william-blair/1817087.html.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.